0001104659-21-038386.txt : 20210318 0001104659-21-038386.hdr.sgml : 20210318 20210318163256 ACCESSION NUMBER: 0001104659-21-038386 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20210317 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210318 DATE AS OF CHANGE: 20210318 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OMEGA HEALTHCARE INVESTORS INC CENTRAL INDEX KEY: 0000888491 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 383041398 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11316 FILM NUMBER: 21754781 BUSINESS ADDRESS: STREET 1: 303 INTERNATIONAL CIRCLE, STREET 2: SUITE 200 CITY: HUNT VALLEY STATE: MD ZIP: 21030 BUSINESS PHONE: 410-427-1700 MAIL ADDRESS: STREET 1: 303 INTERNATIONAL CIRCLE, STREET 2: SUITE 200 CITY: HUNT VALLEY STATE: MD ZIP: 21030 8-K 1 tm2110161d1_8k.htm FORM 8-K
0000888491 false 0000888491 2021-03-17 2021-03-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 17, 2021

 

OMEGA HEALTHCARE INVESTORS, INC.

(Exact name of registrant as specified in its charter)

 

Maryland 1-11316 38-3041398
(State or other jurisdiction of
incorporation)		 (Commission File Number) (IRS Employer
Identification No.)

  

303 International Circle

Suite 200

Hunt Valley, Maryland 21030

(Address of principal executive offices / Zip Code)

 

(410) 427-1700

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act.

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

 

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934: 

     
Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common Stock, $.10 par value OHI New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 8.01 Other Events.

 

On March 17, 2021, Omega Healthcare Investors, Inc. (the “Company”) announced the early tender results and pricing for its previously announced tender offer (the “Tender Offer”) to purchase for cash up to an aggregate principal amount of $350 million (the “Aggregate Maximum Tender Amount”) of its 4.375% Senior Notes due 2023 (the “Notes”). The Tender Offer is being made exclusively pursuant to an offer to purchase, dated March 3, 2021, as amended by a press release on March 3, 2021, which set forth the terms and conditions of the Tender Offer.

 

In order to have received additional consideration for tendering early, holders of Notes must have validly tendered and not validly withdrawn their Notes prior to or at 5:00 p.m., New York City Time, on March 16, 2021 (the “Early Tender Time”). At the Early Tender Time, holders had validly tendered and not validly withdrawn $441.61 million of the $700 million aggregate principal amount outstanding of the Notes. On March 18, 2021, the Company accepted for purchase $350 million aggregate principal amount of notes that were validly tendered and not validly withdrawn pursuant to the Tender Offer.

 

Because the aggregate principal amount of the Notes validly tendered and not validly withdrawn exceeded the Aggregate Maximum Tender Amount, the Company did not accept for purchase all of the Notes that were validly tendered and not validly withdrawn and only accepted for purchase the Aggregate Maximum Tender Amount of those Notes. Accordingly, the Notes validly tendered and not validly withdrawn were subject to proration. The Company used a proration rate of approximately 79.41% for the Notes. The Notes tendered by each holder were multiplied by the proration rate and then rounded down to the nearest $1,000 increment; provided that if less than all of a holder’s tendered Notes were accepted for purchase, such holder was required to continue to hold Notes in the minimum authorized denomination of $2,000 principal amount.

 

Since the Tender Offer for the Notes was fully subscribed as of the Early Tender Time, the Company will not accept for purchase any Notes validly tendered after the Early Tender Time.

 

The Tender Offer will expire at 11:59 p.m., New York City Time, at the end of March 30, 2021, unless earlier terminated.

 

Copies of the press releases announcing the early tender results and pricing, respectively, of the Tender Offer, are attached hereto as Exhibits 99.1 and 99.2 and are incorporated in this Item 8.01 by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits. The following exhibits are being filed herewith:

 

No.   Description
99.1   Press Release Announcing Early Tender Results, dated March 17, 2021
99.2   Press Release Announcing Pricing, dated March 17, 2021
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  OMEGA HEALTHCARE INVESTORS, INC.
     
     
Dated:  March 18, 2021 By: /s/ Gail D. Makode
    Gail D. Makode
    Chief Legal Officer, General Counsel and Secretary

 

 

 

 EX-99.1 2 tm2110161d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

303 International Circle

Suite 200

Hunt Valley, MD 21030

P: 410.427.1700

F: 410.427.8800

PRESS RELEASE – FOR IMMEDIATE RELEASE

 

Omega Healthcare Investors, Inc. Announces Early Tender Results of Tender Offer for Outstanding Notes

 

HUNT VALLEY, MARYLAND – March 17, 2021 – Omega Healthcare Investors, Inc. (NYSE: OHI) (“Omega”) announced today the early tender results for its previously announced tender offer (the “Tender Offer”) to purchase for cash up to an aggregate principal amount of $350 million (the “Aggregate Maximum Tender Amount”) of its 4.375% Senior Notes due 2023 (the “Notes”).

 

Title of Note CUSIP Number Principal
Amount
Outstanding		 Aggregate
Maximum
Tender
Amount		 Principal Amount Tendered at Early Tender Time Principal Amount Accepted
4.375%
Senior Notes
due 2023		 681936BJ8 $700
million		 $350 million $441,610,000 $350,000,000

 

The terms and conditions of the Tender Offer are set forth in the offer to purchase, dated March 3, 2021, as amended by press release on March 3, 2021 (as the same may be further amended or supplemented, the “Offer to Purchase”). The Tender Offer will expire at 11:59 p.m., New York City Time, at the end of March 30, 2021, unless earlier terminated.

 

As of 5:00 p.m., New York City Time, on March 16, 2021 (such date and time, as it may be extended, the “Early Tender Time”), according to information provided by Global Bondholder Services Corporation, the tender and information agent for the Tender Offer, the aggregate principal amount of the Notes set forth in the table above under “Principal Amount Tendered at Early Tender Time” had been validly tendered and not validly withdrawn in the Tender Offer. Withdrawal rights for the Notes expired at 5:00 p.m., New York City Time, on March 16, 2021.

 

The “Total Consideration” for each $1,000 principal amount of Notes validly tendered and accepted for purchase pursuant to the Tender Offer will be determined in the manner described in the Offer to Purchase by reference to the fixed spread for the Notes specified in the table above plus the yield based on the bid-side price of the U.S. Treasury Reference Security specified in the table above at 10:00 a.m., New York City Time, today, and is inclusive of the Early Tender Premium (as set forth in the table above).

 

Omega expects to announce the pricing of the Tender Offer, the amount of Notes accepted for purchase, and the proration rates for the Notes later today.

 

Only holders of Notes who validly tendered and did not validly withdraw their Notes at or prior to the Early Tender Time are eligible to receive the Total Consideration for the Notes accepted for purchase. Holders of Notes will also receive accrued and unpaid interest on their Notes validly tendered and accepted for purchase from the last interest payment date up to, but not including, the settlement date.

 

Omega has satisfied the financing condition to the Tender Offer and, on March 18, 2021, expects to pay for the Notes that were validly tendered prior to or at the Early Tender Time and that are accepted for purchase.

 

Since the Tender Offer for the Notes was fully subscribed as of the Early Tender Time, Omega will not accept for purchase any Notes validly tendered after the Early Tender Time.

 

 

 

 

Information Relating to the Tender Offer

 

Credit Agricole Securities (USA) Inc. is serving as the Lead Dealer Manager for the Tender Offer. Investors with questions regarding the Tender Offer may contact the Lead Dealer Manager by phone at (866) 807-6030 (Toll Free) or (212) 261-7802 (Collect), by email at us.liabilitymanagement@ca-cib.com, or by mail addressed to Credit Agricole Securities (USA) Inc. at 1301 Avenue of the Americas, 17th Floor, New York, NY 10019, Attention: Debt Capital Markets/Liability Management.

 

None of Omega or its affiliates, their respective boards of directors, the dealer managers, the tender and information agent or the trustee with respect to the Notes is making any recommendation as to whether holders should tender any Notes in response to the Tender Offer, and neither Omega nor any such other person has authorized any person to make any such recommendation. Holders must make their own decision as to whether to tender any of their Notes, and, if so, the principal amount of Notes to tender.

 

This press release is for informational purposes only and is not an offer to buy, or the solicitation of an offer to sell, any of the Notes and the Tender Offer does not constitute an offer to buy or the solicitation of an offer to sell the Notes in any jurisdiction or in any circumstances in which such offer or solicitation are unlawful. The full details of the Tender Offer, including complete instructions on how to tender the Notes, are included in the Offer to Purchase. Holders are strongly encouraged to carefully read the Offer to Purchase, including materials incorporated by reference therein, because they contain important information. The Offer to Purchase may be downloaded from Global Bondholder Services Corporation’s website at www.gbsc-usa.com/omega/ or obtained from Global Bondholder Services Corporation, free of charge, by calling toll free at (866) 470-4300 (bankers and brokers can call collect at (212) 430-3774).

 

About Omega

 

Omega is a real estate investment trust that invests in the long-term healthcare industry, primarily in skilled nursing and assisted living facilities. Its portfolio of assets is operated by a diverse group of healthcare companies, predominantly in a triple-net lease structure. The assets span all regions within the United States, as well as in the United Kingdom. More information on Omega is available at www.omegahealthcare.com.

 

Forward-Looking Statements

 

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding Omega’s or its tenants’, operators’, borrowers’ or managers’ expected future financial condition, results of operations, cash flows, funds from operations, dividends and dividend plans, financing opportunities and plans, capital markets transactions, business strategy, budgets, projected costs, operating metrics, capital expenditures, competitive positions, acquisitions, investment opportunities, dispositions, facility transitions, growth opportunities, continued qualification as a real estate investment trust, plans and objectives of management for future operations and statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will” and other similar expressions are forward-looking statements. These forward-looking statements are inherently uncertain, and actual results may differ from Omega’s expectations.

 

Omega’s actual results may differ materially from those reflected in such forward-looking statements as a result of a variety of factors, including, among other things: (i) uncertainties relating to the business operations of the operators of Omega’s properties, including those relating to reimbursement by third-party payors, regulatory matters and occupancy levels; (ii) the impact of novel coronavirus (“COVID-19”) on our business and the business of our operators, including without limitation, the extent and duration of the COVID-19 pandemic, increased costs experienced by operators of skilled nursing facilities and assisted living facilities in connection therewith, and the extent to which continued government support may be available to operators to offset such costs and the conditions related thereto; (iii) the ability of our operators to comply with the terms and conditions pursuant to which government support may be available; (iv) the risk Omega may not complete this offering in a timely fashion or at all, and (v) those risks and uncertainties associated with Omega’s business described in its Annual Report on Form 10-K filed on February 28, 2020 and its subsequent filings with the Securities and Exchange Commission. Although Omega believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, Omega can give no assurance that the expectations will be attained or that any deviation will not be material. We caution you that the foregoing list of important factors may not contain all of the material factors that are important to you. Accordingly, readers should not place undue reliance on those statements. All forward-looking statements are based upon information available to us on the date of this release. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

 

Contact

 

Bob Stephenson, CFO, or Matthew Gourmand, SVP Corporate Strategy & Investor Relations, at (410) 427-1700.

 

 

 

 EX-99.2 3 tm2110161d1_ex99-2.htm EXHIBIT 99.2

 

Exhibit 99.2

 

303 International Circle

Suite 200

Hunt Valley, MD 21030

P: 410.427.1700

F: 410.427.8800

PRESS RELEASE – FOR IMMEDIATE RELEASE

 

Omega Healthcare Investors, Inc. Announces Pricing of Tender Offer

 

HUNT VALLEY, MARYLAND – March 17, 2021 – Omega Healthcare Investors, Inc. (NYSE: OHI) (“Omega”) announced today the consideration payable in connection with its previously announced tender offer (the “Tender Offer”) to purchase for cash up to an aggregate principal amount of $350 million (the “Aggregate Maximum Tender Amount”) of its 4.375% Senior Notes due 2023 (the “Notes”) as described in the table below.

 

Title of Note CUSIP Number Principal
Amount
Outstanding		 Aggregate
Maximum
Tender
Amount		 U.S.
Treasury
Reference
Security		 U.S. Treasury Reference Security Yield Bloomberg
Reference
Page		 Fixed
Spread		 Early
Tender
Premium
(1)(2)		 Applicable Par Call
Date

Total

Consideration

(1)(2)

4.375%
Senior Notes
due 2023		 681936BJ8 $700
million		 $350 million 1.625%
UST due
5/31/2023		 0.204% FIT5 +50 bps $30 June 1, 2023 $1,080.09

 

(1)Per $1,000 principal amount.

 

(2)The Total Consideration for Notes validly tendered prior to or at the Early Tender Time (as defined below) and accepted for purchase is calculated using the applicable Fixed Spread (as set forth in the table above) and is inclusive of the Early Tender Premium (as set forth in the table above).

 

The Tender Offer was made on the terms and conditions set forth in the Offer to Purchase, dated March 3, 2021, as amended by press release on March 3, 2021 (as the same may be further amended or supplemented, the “Offer to Purchase”). The Tender Offer will expire at 11:59 p.m., New York City Time, at the end of March 30, 2021, unless earlier terminated.

 

The “Total Consideration” for each $1,000 principal amount of the Notes validly tendered and accepted for purchase pursuant to the Tender Offer was determined in the manner described in the Offer to Purchase by reference to the fixed spread for the Notes specified in the table above plus the yield based on the bid-side price of the U.S. Treasury Reference Security specified in the table above at 10:00 a.m., New York City Time, today.

 

Only holders of Notes who validly tendered and did not validly withdraw their Notes at or prior to 5:00 p.m., New York City Time, on March 16, 2021 (such date and time, as it may be extended with respect to a Tender Offer, the “Early Tender Time”) are eligible to receive the Total Consideration for such Notes accepted for purchase. Holders of the Notes will also receive accrued and unpaid interest on their Notes validly tendered and accepted for purchase from the last interest payment date up to, but not including, the settlement date. Withdrawal rights for the Notes expired at 5:00 p.m., New York City Time, on March 16, 2021. On March 18, 2021, Omega expects to pay for the Notes that were validly tendered prior to or at the Early Tender Time and that are accepted for purchase.

 

Because the aggregate principal amount of the Notes validly tendered and not validly withdrawn exceeds the Aggregate Maximum Tender Amount, Omega will not accept for purchase all of the Notes that have been validly tendered and not validly withdrawn and will only accept for purchase the Aggregate Maximum Tender Amount of those Notes. Accordingly, the Notes validly tendered and not validly withdrawn will be subject to proration. The Company will use a proration rate of approximately 79.41% for the Notes. The Notes tendered by a holder will be multiplied by the proration rate and then rounded down to the nearest $1,000 increment; provided that if less than all of a holder’s tendered Notes are accepted for purchase, such holder must continue to hold Notes in the minimum authorized denomination of $2,000 principal amount.

 

 

 

 

Since the Tender Offer for the Notes was fully subscribed as of the Early Tender Time, Omega will not accept for purchase any Notes validly tendered after the Early Tender Time.

 

Information Relating to the Tender Offer

 

Credit Agricole Securities (USA) Inc. is serving as the Lead Dealer Manager for the Tender Offer. Investors with questions regarding the Tender Offer may contact the Lead Dealer Manager by phone at (866) 807-6030 (Toll Free) or (212) 261-7802 (Collect), by email at us.liabilitymanagement@ca-cib.com, or by mail addressed to Credit Agricole Securities (USA) Inc. at 1301 Avenue of the Americas, 17th Floor, New York, NY 10019, Attention: Debt Capital Markets/Liability Management.

 

None of Omega or its affiliates, their respective boards of directors, the dealer managers, the tender and information agent or the trustee with respect to the Notes is making any recommendation as to whether holders should tender any Notes in response to the Tender Offer, and neither Omega nor any such other person has authorized any person to make any such recommendation. Holders must make their own decision as to whether to tender any of their Notes, and, if so, the principal amount of Notes to tender.

 

This press release is for informational purposes only and is not an offer to buy, or the solicitation of an offer to sell, any of the Notes and the Tender Offer does not constitute an offer to buy or the solicitation of an offer to sell the Notes in any jurisdiction or in any circumstances in which such offer or solicitation are unlawful. The full details of the Tender Offer, including complete instructions on how to tender the Notes, are included in the Offer to Purchase. Holders are strongly encouraged to carefully read the Offer to Purchase, including materials incorporated by reference therein, because they contain important information. The Offer to Purchase may be downloaded from Global Bondholder Services Corporation’s website at www.gbsc-usa.com/omega/ or obtained from Global Bondholder Services Corporation, free of charge, by calling toll free at (866) 470-4300 (bankers and brokers can call collect at (212) 430-3774).

 

About Omega

 

Omega is a real estate investment trust that invests in the long-term healthcare industry, primarily in skilled nursing and assisted living facilities. Its portfolio of assets is operated by a diverse group of healthcare companies, predominantly in a triple-net lease structure. The assets span all regions within the United States, as well as in the United Kingdom. More information on Omega is available at www.omegahealthcare.com.

 

 

 

 

Forward-Looking Statements

 

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding Omega’s or its tenants’, operators’, borrowers’ or managers’ expected future financial condition, results of operations, cash flows, funds from operations, dividends and dividend plans, financing opportunities and plans, capital markets transactions, business strategy, budgets, projected costs, operating metrics, capital expenditures, competitive positions, acquisitions, investment opportunities, dispositions, facility transitions, growth opportunities, continued qualification as a real estate investment trust, plans and objectives of management for future operations and statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will” and other similar expressions are forward-looking statements. These forward-looking statements are inherently uncertain, and actual results may differ from Omega’s expectations.

 

Omega’s actual results may differ materially from those reflected in such forward-looking statements as a result of a variety of factors, including, among other things: (i) uncertainties relating to the business operations of the operators of Omega’s properties, including those relating to reimbursement by third-party payors, regulatory matters and occupancy levels; (ii) the impact of novel coronavirus (“COVID-19”) on our business and the business of our operators, including without limitation, the extent and duration of the COVID-19 pandemic, increased costs experienced by operators of skilled nursing facilities and assisted living facilities in connection therewith, and the extent to which continued government support may be available to operators to offset such costs and the conditions related thereto; (iii) the ability of our operators to comply with the terms and conditions pursuant to which government support may be available; (iv) the risk Omega may not complete this offering in a timely fashion or at all, and (v) those risks and uncertainties associated with Omega’s business described in its Annual Report on Form 10-K filed on February 28, 2020 and its subsequent filings with the Securities and Exchange Commission. Although Omega believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, Omega can give no assurance that the expectations will be attained or that any deviation will not be material. We caution you that the foregoing list of important factors may not contain all of the material factors that are important to you. Accordingly, readers should not place undue reliance on those statements. All forward-looking statements are based upon information available to us on the date of this release. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

 

Contact

 

Bob Stephenson, CFO, or Matthew Gourmand, SVP Corporate Strategy & Investor Relations, at (410) 427-1700.

 

 

 EX-101.SCH 4 ohi-20210317.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 ohi-20210317_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 ohi-20210317_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 image_001.jpg GRAPHIC begin 644 image_001.jpg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tm2110161d1_8k_htm.xml IDEA: XBRL DOCUMENT 0000888491 2021-03-17 2021-03-17 iso4217:USD shares iso4217:USD shares 0000888491 false 8-K 2021-03-17 OMEGA HEALTHCARE INVESTORS, INC. MD 1-11316 38-3041398 303 International Circle Suite 200 Hunt Valley MD 21030 410 427-1700 false false false false Common Stock, $.10 par value OHI NYSE false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.20.4
Cover
Mar. 17, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 17, 2021
Entity File Number 1-11316
Entity Registrant Name OMEGA HEALTHCARE INVESTORS, INC.
Entity Central Index Key 0000888491
Entity Tax Identification Number 38-3041398
Entity Incorporation, State or Country Code MD
Entity Address, Address Line One 303 International Circle
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Hunt Valley
Entity Address, State or Province MD
Entity Address, Postal Zip Code 21030
City Area Code 410
Local Phone Number 427-1700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $.10 par value
Trading Symbol OHI
Security Exchange Name NYSE
Entity Emerging Growth Company false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.4 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://omegahealthcare.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2110161d1_8k.htm ohi-20210317.xsd ohi-20210317_lab.xml ohi-20210317_pre.xml tm2110161d1_ex99-1.htm tm2110161d1_ex99-2.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2110161d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2110161d1_8k.htm" ] }, "labelLink": { "local": [ "ohi-20210317_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "ohi-20210317_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "ohi-20210317.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ohi", "nsuri": "http://omegahealthcare.com/20210317", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2110161d1_8k.htm", "contextRef": "From2021-03-17to2021-03-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://omegahealthcare.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2110161d1_8k.htm", "contextRef": "From2021-03-17to2021-03-17", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://omegahealthcare.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 16 0001104659-21-038386-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-038386-xbrl.zip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end